Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non‐valvular atrial fibrillation
Pharmacoepidemiology and Drug Safety · 2024
DOI: 10.1002/pds.5733 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2024. Verfasst von T Álvaro Thomsen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Maternal Child Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain. Hauptthemen laut MEDLINE: Stroke, Atrial Fibrillation, Ischemic Stroke. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Themen: Schlaganfall
Abstract (Originalsprache)
Introduction
Although direct oral anticoagulants' (DOACs) prescriptions have experienced immense growth in the last decade, the proportion of discontinuers is still common yielding an increased risk of ischemic stroke (IS) onset.
Aims
We aimed to estimate the association between DOACs discontinuation and risk of IS among patients with non‐valvular atrial fibrillation (NVAF).
Methods
We used data from a cohort of new DOACs users, followed patients from the first DOAC prescription date up to IS (index date) and conducted a nested case–control analysis using conditional logistic regression. Adjusted odds ratios, 95% confidence intervals were calculated for discontinuation of DOACs (current use compared with past use). The latter, subdivided among those stopping treatment 3 to 2 months and 6 and 3 months prior to index date. The effect of naïve current users against IS onset compared with non‐naïve current users was also evaluated.
Results
DOACs discontinuation showed an OR of IS of 1.47 (95% CI: 1.02–2.12); estimates were 2.51 (95% CI: 1.84–3.42) for whom discontinued treatment within months 3 and 2 and 1.43 (95% CI: 0.96–2.13) for those between months 6 and 3 prior to index date. Analyzing DOACs individually, risk of IS associated with past users compared with current users: 1.98 (95% CI: 1.25–3.12) for apixaban, 1.38 (95% CI: 0.40–4.72) for edoxaban, 1.98 (95% CI: 1.24–2.65) for dabigatran and 1.87 (95% CI: 1.26–2.76) for rivaroxaban. Similar results were found when stratified by naïve and non‐naïve users.
Conclusions
DOACs' discontinuation is associated with higher risk of IS, especially in the second and third months following interruption.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health and Maternal Child Health, Faculty of Medicine, Complutense University of Madrid, Madrid, Spain.
- BIFAP, Division of Pharmacoepidemiology and Pharmacovigilance, Spanish Agency for Medicines and Medical Devices (AEMPS), Madrid, Spain.
ORCID-Profile: J Mesa Guadalupe, C Huerta, A de Burgos
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Álvaro Thomsen, T., Mesa Guadalupe, J., Huerta, C., de Burgos, A., & Cea Soriano, L. (2024). Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non‐valvular atrial fibrillation. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5733
Vancouver
Álvaro Thomsen T, Mesa Guadalupe J, Huerta C, de Burgos A, Cea Soriano L. Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non‐valvular atrial fibrillation. Pharmacoepidemiology and Drug Safety. 2024. doi:10.1002/pds.5733
BibTeX
@article{lvaroThomsen2024,
author = {Álvaro Thomsen, T and Mesa Guadalupe, J and Huerta, C and de Burgos, A and Cea Soriano, L},
title = {Risk of ischemic stroke associated with direct oral anticoagulants discontinuation on patients with non‐valvular atrial fibrillation},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2024},
doi = {10.1002/pds.5733}
}
EUVIMED